NASDAQ:CELC

Celcuity (CELC) Stock Price, News & Analysis

$16.76
-0.90 (-5.10%)
(As of 05/17/2024 ET)
Today's Range
$16.38
$17.66
50-Day Range
$15.77
$21.60
52-Week Range
$8.39
$22.19
Volume
230,349 shs
Average Volume
217,519 shs
Market Capitalization
$510.34 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$29.50

Celcuity MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
76.0% Upside
$29.50 Price Target
Short Interest
Bearish
6.24% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.40mentions of Celcuity in the last 14 days
Based on 17 Articles This Week
Insider Trading
Selling Shares
$10,924 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.93) to ($3.62) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.06 out of 5 stars

Medical Sector

504th out of 922 stocks

Medical Laboratories Industry

13th out of 19 stocks

CELC stock logo

About Celcuity Stock (NASDAQ:CELC)

Celcuity Inc., a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, advanced or metastatic breast cancer, and metastatic castration resistant prostate cancer. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.

CELC Stock Price History

CELC Stock News Headlines

Growth Potential Drives Buy Rating for Celcuity Despite Current Losses
Celcuity Non-GAAP EPS of -$0.59
Celcuity (CELC) to Announce Quarterly Earnings on Wednesday
Celcuity Gains 12%, Insider Trades Reap Benefit
Q4 2023 Celcuity Inc Earnings Call
Recap: Celcuity Q4 Earnings
CELC Apr 2024 20.000 call
See More Headlines
Receive CELC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Celcuity and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/27/2024
Today
5/17/2024
Next Earnings (Estimated)
8/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Medical laboratories
Sub-Industry
N/A
Current Symbol
NASDAQ:CELC
Fax
N/A
Employees
55
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$29.50
High Stock Price Target
$40.00
Low Stock Price Target
$24.00
Potential Upside/Downside
+76.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-63,780,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$5.48 per share

Miscellaneous

Free Float
23,056,000
Market Cap
$510.34 million
Optionable
Optionable
Beta
0.87
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Mr. Brian F. Sullivan (Age 62)
    Co-Founder, Chairman & CEO
    Comp: $478.12k
  • Dr. Lance G. Laing Ph.D. (Age 62)
    Co-Founder, Chief Science Officer, VP, Secretary & Director
    Comp: $389.55k
  • Ms. Vicky Hahne (Age 58)
    Chief Financial Officer
    Comp: $281.59k
  • Dr. John R. MacDonald Dabt (Age 69)
    Ph., Ph.D., Senior Vice President of R&D
  • Ms. Sheri Smith
    Acting Head of Clinical Operations
  • Mr. Igor Gorbatchevsky M.D.
    Chief Medical Officer
  • Mr. Eldon C. Mayer III (Age 63)
    M.B.A., Chief Commercial Officer

CELC Stock Analysis - Frequently Asked Questions

Should I buy or sell Celcuity stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Celcuity in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CELC shares.
View CELC analyst ratings
or view top-rated stocks.

What is Celcuity's stock price target for 2024?

4 Wall Street research analysts have issued twelve-month price targets for Celcuity's shares. Their CELC share price targets range from $24.00 to $40.00. On average, they expect the company's share price to reach $29.50 in the next year. This suggests a possible upside of 76.0% from the stock's current price.
View analysts price targets for CELC
or view top-rated stocks among Wall Street analysts.

How have CELC shares performed in 2024?

Celcuity's stock was trading at $14.57 on January 1st, 2024. Since then, CELC shares have increased by 15.0% and is now trading at $16.76.
View the best growth stocks for 2024 here
.

When is Celcuity's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024.
View our CELC earnings forecast
.

How were Celcuity's earnings last quarter?

Celcuity Inc. (NASDAQ:CELC) issued its quarterly earnings data on Wednesday, March, 27th. The company reported ($0.65) EPS for the quarter, topping analysts' consensus estimates of ($0.71) by $0.06.

What ETF holds Celcuity's stock?

Jacob Forward ETF holds 1,688 shares of CELC stock, representing 1.01% of its portfolio.

What other stocks do shareholders of Celcuity own?
When did Celcuity IPO?

Celcuity (CELC) raised $18 million in an initial public offering (IPO) on Wednesday, September 20th 2017. The company issued 2,000,000 shares at $8.00-$10.00 per share. Craig-Hallum Capital Group acted as the underwriter for the IPO.

Who are Celcuity's major shareholders?

Celcuity's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Baker BROS. Advisors LP (5.10%), Vanguard Group Inc. (2.72%), Healthcare of Ontario Pension Plan Trust Fund (0.54%), BNP Paribas Financial Markets (0.03%), SG Americas Securities LLC (0.02%) and California State Teachers Retirement System (0.01%). Insiders that own company stock include Brian F Sullivan, David Dalvey, Richard E Buller and Richard Nigon.
View institutional ownership trends
.

How do I buy shares of Celcuity?

Shares of CELC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CELC) was last updated on 5/18/2024 by MarketBeat.com Staff

From Our Partners